Loading
A phase 1 trial of BPX-603 run by Bellicum Pharmaceuticals, suspended.
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors is a phase 1 interventional study registered as NCT04650451 by Bellicum Pharmaceuticals, with 220 participants planned, started 2020-12-07. Conditions recorded: HER-2 Gene Amplification, HER2-positive Gastric Cancer, HER2-positive Breast Cancer, HER-2 Protein Overexpression and Solid Tumor, Adult. Interventions recorded: chimeric antigen receptor (CAR) T cell therapy.
Shares Bellicum Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bellicum Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares HER2-positive gastric cancer, HER2-positive breast cancer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bellicum Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares HER2-positive gastric cancer, HER2-positive breast cancer and the tag pipeline.
Shares Bellicum Pharmaceuticals and the tag pipeline.
Shares HER2-positive gastric cancer and the tag pipeline.
Shares Bellicum Pharmaceuticals and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/